KNSA jumps 22% on earnings day as options lean bullish

Kiniksa Pharmaceuticals delivered its sharpest single-day move in months on October 27, jumping 22% to $89.20 after reporting results, and the options market had been leaning that way well before the print.

The clearest pre-earnings signal was in call positioning. The put/call ratio has fallen steadily over the past month, dropping from around 0.19 in late September to 0.13 on the day of the release, well below its 20-day average of 0.15. That level sits near the lower end of the past year's range, whose 52-week low was 0.01, indicating options traders were carrying far more upside exposure than downside protection heading into results. Short interest, at 8.5% of the free float with roughly 3.84 million shares short, edged up about 7% over the week but remains well within the recent range. Borrow conditions add no tension to that story: cost to borrow is just 0.53%, down about 9% on the week, and availability is extremely loose at over 1,500%, meaning there are roughly 15 shares available to borrow for every one already lent out. Shorts are present but not under pressure.

The Street's reaction to prior quarters helps explain the bullish lean. Analysts swept their targets higher after the Q1 print in late July. Goldman Sachs raised to $90, JP Morgan to $107, Citigroup to $100, Wedbush to $99, and Canaccord Genuity to $98, all maintaining existing positive ratings. The mean price target now sits at roughly $104, leaving the stock about 16% below the consensus even after Tuesday's surge. The bull case centres on Arcalyst's commercial momentum: Q1 revenue of $214.3 million, up 56% year-over-year, and management subsequently raised full-year 2026 guidance to $930 to $945 million. With only around 18% of the estimated 14,000 multiple-recurrence recurrent pericarditis patients currently on therapy, the penetration runway is a core part of the investment case. Bears counter that the valuation prices in near-perfect execution, and that competitive products or pricing pressure on biologics in rare disease could erode that premium over time. The PE multiple, at around 54 times trailing earnings, has expanded roughly 7 points in a single session following the jump. EV/EBITDA sits near 25 times, up about 5 points on the day.

On the register, there is a 13D activist filer: Julian C. Baker filed a Schedule 13D/A in May 2026, disclosing a 7.0% stake. A 13D filing signals active rather than passive intent, making Baker a name worth watching. FMR LLC remains the largest institutional holder at roughly 8.9% of shares, and BlackRock added aggressively through the year, with its last reported position reflecting a jump from about 1% to 5.5% of the class. Rubric Capital, another sizeable holder, trimmed from 9.24% to 7.37% earlier in the year. Insider activity over the past 90 days is modest and mechanical: the only open-market sale was 4,600 shares by the Chief Accounting Officer in early September under a pre-arranged 10b5-1 plan, worth around $369,000. CEO Sanjiv Patel exercised options on September 1 but the related tax-withholding sale was the only cash transaction, and that structure is standard compensation mechanics rather than a conviction signal.

The alt data adds one piece of colour worth noting. Wikipedia views of the Kiniksa page registered a retail attention z-score of 6.85 as of October 19, an unusually high reading that suggests the October 27 earnings catalyst drew significant retail interest ahead of and around the event. There are no measured datasets that have been shown to lead Kiniksa's reported financials, so that reading describes attention rather than revenue direction.

With the stock now trading above Goldman's $90 target and within range of the JP Morgan $107 level, the next focus is on whether the Street updates its models following this week's print and whether those targets move again. The next earnings event is currently scheduled for late February 2027, giving the market roughly four months to decide how much of the penetration story is already in the price.